Pharmacokinetics of repaglinide in subjects with renal impairment

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 1, 2000, Pages 7-15

  Marbury, Thomas C ^a   Ruckle, Jon L ^a   Hatorp, Vibeke ^b   Andersen, Michael P ^b   Nielsen, Karin Kramer ^c   Huang, Won Chin ^c   Strange, Poul ^d  

^a ORLANDO CLINICAL RESEARCH CENTER   (United States)

^b Northwest Kinetics   (United States)

^c NOVO NORDISK A S   (Denmark)

^d NOVO NORDISK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

REPAGLINIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STEADY STATE;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CARBAMATES; CREATININE; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN BINDING; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX;

EID: 0033950125     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.103973     Document Type: Article

References (16)

1. 1. Badian M, Korn A, Lehr KH, Malerczyk V, Waldhausl W. Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration. Drug Metabol Drug Interact 1996; 13:69-85.
2. 2. Petitpierre B, Perrin L, Rudhardt M, Herrera A, Fabre J. Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy. Int J Clin Pharmacol 1972;6:120-4.
3. 3. Rabkin R, Simon NM, Steiner S, Colwell JA. Effect of renal disease on renal uptake and excretion of insulin in man. N Engl J Med 1970;282:182-7.
4. 4. DeFronzo RA. Diabetic nephropathy: etiologic and therapeutic considerations. Diabetes Rev 1995;3:510-62.
5. 5. Henquin JC, Garrino MG, Nenquin M. Stimulation of insulin release by benzoic acid derivatives related to the non-sulphonylurea moiety of glibenclamide: structural requirements and cellular mechanisms. Eur J Pharmacol 1987;141:243-51.
6. 6. Hatorp V, Oliver S, Su CAPF. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. Int J Clin Pharmacol Ther 1998;36:636-41.
7. 7. Chow MS, Wang F. Focus on repaglinide: an oral hypoglycemic agent with a more rapid onset and shorter duration of action than the sulfonylureas. Formulary 1998;33: 409-19.
8. 8. Balfour JA, Faulds D. Repaglinide. Drugs Aging 1998;13: 173-80.
9. 9. Kikuchi M. Modulation of insulin secretion in noninsulin-dependent diabetes mellitus by two novel oral hypoglycemic agents, NN623 and A4166. Diabet Med 1996;13:S151-5.
10. 14C] repaglinide in human, cynomolgus monkey, dog, rabbit, rat and mouse [abstract]. Diabetologia 1997;40(suppl 1):A326.
11. 14C-repaglinide during non-labeled repaglinide multiple dosing [abstract]. Diabetes 1998;47(suppl 1):A355.
12. 12. Ferner RE, Chaplin S. The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Clin Pharmacokinet 1987;12:379-401.
13. 13. Wrighton SA, Stevens JC. The human hepatic cytochrome P-450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
14. 14. Harrower ADB. Pharmacokinetics of oral anti-hypoglycemic agents in patients with renal insufficiency. Clin Pharmacokinet 1996;31:111-9.
15. 15. Lam FYW, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997;32:30-57.
16. 16. Damsbo P, Perentesis G, Muller PG, Hatorp V. Favorable tolerability profile of repaglinide in NIDDM after multiple ascending doses [abstract]. J Clin Pharmacol 1997;37: 875.